Clinical Trials Logo

Esophageal Disease clinical trials

View clinical trials related to Esophageal Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04001400 Completed - Esophageal Disease Clinical Trials

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Start date: October 10, 2012
Phase: Phase 3
Study type: Interventional

This is a single-center, randomized, open-label clinical study to assess the treatment response of high-dose rabeprazole compared with standard-dose rabeprazole in patients with extra-esophageal manifestations of gastroesophageal reflux disease.

NCT ID: NCT03998969 Completed - Esophageal Disease Clinical Trials

Efficacy of DA-5204 on Gastroesophageal Reflux Disease

Start date: June 1, 2016
Phase: Phase 3
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled clinical Study to evaluate the efficacy of DA-5204 and proton pump inhibitor combination therapy compared with proton pump inhibitor alone therapy in patients with gastroesophageal reflux Disease.

NCT ID: NCT02105506 Completed - Gastric Disease Clinical Trials

Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses

SAFE-T
Start date: September 2012
Phase: N/A
Study type: Interventional

Rationale: The construction of esophageal anastomoses is associated with considerable risk at postoperative anastomotic leakage. Application of TachoSil®, a tissue sealant with human fibrinogen and thrombin, can improve strength of the esophageal anastomosis and potentially prevent anastomotic leakage. Objective: Evaluation of feasibility and safety of TachoSil® application on esophageal anastomoses. Study design: Non-randomized, non-blinded, single-center intervention study. Study population: Patients, 18-80 years old, undergoing an elective total gastrectomy with an esophago-jejunostomy or esophagectomy with a planned esophagogastric anastomosis will be enrolled. A total number of 15 patients will be included in the study. Intervention: Gastric or esophageal resection will be executed according to the common procedures used in the UMC Utrecht. After construction of the esophageal anastomosis, all enrolled participants will receive a TachoSil® patch, which will be applied on the esophageal anastomosis intra-operatively. Hence, TachoSil® is used as an add-on therapy. TachoSil® will be degraded enzymatically in a period of approximately 24 weeks after application. Main study parameters/endpoints: The primary endpoint is feasibility, which is assessed by evaluation of adherence of the patch. A time-action analysis of the application of the Tachosil patch will be performed. Nature and extent of the burden associated with participation: The burden for the patient is minimal. The total surgical procedure will be prolonged with 10-15 minutes. Postoperative care and outpatient visits do not differ from regular protocol. TachoSil® is approved and registered for supportive treatment in surgery for improvement of haemostasis and to promote tissue sealing by the European Commission.

NCT ID: NCT01927016 Completed - Esophageal Neoplasm Clinical Trials

Outcomes After Esophageal Cancer Surgery

FREGAT I
Start date: July 2012
Phase: N/A
Study type: Observational

Background - Esophageal carcinoma is the sixth leading cause of cancer -related mortality and the eighth most common cancer worldwide - The incidence is increasing rapidly - The overall 5-year survival ranges from 15% to 25% in the literature and poor outcomes are related to diagnosis at advanced stages. - Surgery used to be the cornerstone of treatment of resectable esophageal cancer, but treatment of esophageal carcinoma remains challenging and need to be considered through a multimodal approach. However the modalities and the impact of this multimodal approach at a national level are unknown Primary objective: To identify predictors of recurrence after esophageal cancer surgery Secondary objectives : - 5-year recurrence free survival - 5-year overall survival - Predictors of postoperative mortality and morbidity after surgery - Impact of pCR on recurrence and survival - Impact of neoadjuvant treatments on recurrence and survival - Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes Methodology : European French-speaking retrospective multicentric study Inclusion criteria: All consecutive patients operated on, for a histologically proven carcinoma of the esophagus, the oesophago-gastric junction (Siewert type I and II), in surgical investigator centers between January 2000 and December 2010 Exclusion criteria: Siewert III type carcinoma of the oesophago-gastric junction , non surgical treatment of esophageal carcinoma Planned study period: The data will be collected over a 11-year period from January 2000 to December 2010. Follow up will be ascertained in May 2013.

NCT ID: NCT01360515 Completed - Clinical trials for Gastroesophageal Reflux

A Study of Disposable Transnasal Esophagoscope

Start date: October 2010
Phase: N/A
Study type: Observational

This is a pilot study of a novel disposable transnasal esophagoscope for feasibility, safety and tolerance.